首页> 美国卫生研究院文献>Systematic Reviews >Risk of major bleeding during extended oral anticoagulation in patients with first unprovoked venous thromboembolism: a systematic review and meta-analysis protocol
【2h】

Risk of major bleeding during extended oral anticoagulation in patients with first unprovoked venous thromboembolism: a systematic review and meta-analysis protocol

机译:首次未经批准的静脉血栓栓塞患者长期口服抗凝治疗期间大出血的风险:系统评价和荟萃分析方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundThe optimal duration of anticoagulation after a first unprovoked venous thromboembolism (VTE) remains controversial. Deciding to stop or continue anticoagulant therapy indefinitely after completing 3 to 6 months of initial treatment requires balancing the long-term risk of recurrent VTE if anticoagulation is stopped against the long-term risk of major bleeding if anticoagulation is continued. However, knowledge of the long-term risk for major bleeding events during extended anticoagulation in this patient population is limited. We plan to conduct a systematic review and meta-analysis to quantify the risk for major bleeding events during extended oral anticoagulation in patients with first unprovoked VTE.
机译:背景首次无缘静脉血栓栓塞(VTE)后的最佳抗凝持续时间仍存在争议。决定在完成初始治疗3至6个月后无限期停止或继续抗凝治疗,需要在停止抗凝治疗后长期复发VTE的长期风险与继续进行抗凝治疗后长期出血的长期风险之间取得平衡。但是,对于在该患者人群中进行长期抗凝治疗期间重大出血事件的长期风险的了解是有限的。我们计划进行系统的回顾和荟萃分析,以量化首次未经批准的VTE患者长期口服抗凝治疗期间重大出血事件的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号